Know Cancer

forgot password

A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma

Phase 1
18 Years
95 Years
Open (Enrolling)
Smoldering Multiple Myeloma

Thank you

Trial Information

A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma

This is a dose escalation, phase 1/2a study to assess the safety and tolerability of
PVX-410, (a multi-peptide cancer vaccine), treatment regimen in patients with smoldering
multiple myeloma. Approximately 13 patients will receive six (6)bi-weekly, subcutaneous
injections of PVX-410 for a total of twelve (12) weeks of treatment. Safety will be
monitored throughout the study. Tolerability, immunogenicity and clinical response will
also be measured as described in the protocol.

Inclusion Criteria

- Patient has confirmed clinical diagnosis of SMM according to a definition derived
from the International Myeloma Working Group (IMWG) definition: serum M-protein ≥3
g/dL or bone marrow clonal plasma cells (BMPC) >10%, or both, along with normal organ
and marrow function (CRAB) within 4 weeks before baseline.

- C: Absence of hypercalcemia, evidenced by a calcium <10.5 mg/dL.

- R: Absence of renal failure, evidenced by a creatinine <2.0 mg/dL or calculated
creatinine clearance (using the Modification of Diet in Renal Disease [MDRD] formula)
>50 mL/min.

- A: Absence of anemia, evidenced by a hemoglobin >10 g/dL.

- B: Absence of lytic bone lesions on standard skeletal survey.

- Patient is at higher than average risk of progression to active MM, defined as having
2 or more of the following features:

- Serum monoclonal (M)-protein ≥3 g/dL.

- BMPC >10%.

- Abnormal serum free light chain (FLC) ratio (0.26-1.65).

- Patient has a life expectancy of greater than 6 months

- Patient is human leukocyte antigen (HLA)-A2 positive.

- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or

- Patient has adequate bone marrow function, evidenced by a platelet count ≥75×109/L
and an absolute neutrophil count (ANC) ≥1.0×109/L within 2 weeks before baseline.

- Patient has adequate hepatic function, evidenced by a bilirubin ≤2.0 mg/dL and an
alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5× the upper limit of
normal (ULN) within 2 weeks before baseline.

- If of child-bearing potential, patient agrees to use adequate birth control measures
during study participation.

- If a female of child-bearing potential, patient has negative urine pregnancy test
results within 2 weeks before baseline and is not lactating.

- Patient (or his or her legally accepted representative) has provided written informed
consent to participate in the study.

Exclusion Criteria:

- Patient has symptomatic multiple myeloma, as defined by any of the following:

- Lytic lesions or pathologic fractures.

- Anemia (hemoglobin <10 g/dL).

- Hypercalcemia (corrected serum calcium >11.5 mg/dL).

- Renal insufficiency (creatinine >2 mg/dL).

- Other: symptomatic hyperviscosity, amyloidosis.

- Patient has a history of a prior malignancy within the past 5 years (excluding
resected basal cell carcinoma of the skin or in situ cervical cancer).

- Patient has abnormal cardiac status, evidenced by any of the following:

- New York Heart Association (NYHA) stage III or IV congestive heart failure (CHF).

- Myocardial infarction within the previous 6 months.

- Symptomatic cardiac arrhythmia requiring treatment or persisting despite treatment.

- Patient is receiving any other investigational agent.

- Patient has a current active infectious disease or positive serology for human
immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).

- Patient has a history of or current auto-immune disease.

- Patient has been vaccinated with live attenuated vaccines within 4 weeks before study

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

All adverse events will be recorded.

Outcome Time Frame:

Throughout treatment phase (3 months) and follow up period (12 months)

Safety Issue:


Principal Investigator

Noopur Raje, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Massachusetts General Hospital


United States: Food and Drug Administration

Study ID:




Start Date:

November 2012

Completion Date:

December 2014

Related Keywords:

  • Smoldering Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Massachusetts General HospitalBoston, Massachusetts  02114-2617
University of Texas, MD Anderson Cancer CenterHouston, Texas  77030
Winship Cancer Institute, Emory UniversityAtlanta, Georgia  30322